J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs
Executive Summary
While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year
You may also be interested in...
Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting
Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances